Format

Send to

Choose Destination
Vaccine. 2010 Jun 23;28(29):4653-60. doi: 10.1016/j.vaccine.2010.04.069. Epub 2010 May 14.

The potential economic value of a Staphylococcus aureus vaccine for neonates.

Author information

1
Applied Modeling, Public Health Computational and Operations Research (PHICOR), Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA 15213, USA. BYL1@pitt.edu

Abstract

The continuing morbidity and mortality associated with Staphylococcus aureus (S. aureus) infections, especially methicillin-resistant S. aureus (MRSA) infections, have motivated calls to make S. aureus vaccine development a research priority. We developed a decision analytic computer simulation model to determine the potential economic impact of a S. aureus vaccine for neonates. Our results suggest that a S. aureus vaccine for the neonatal population would be strongly cost-effective (and in many situations dominant) over a wide range of vaccine efficacies (down to 10%) for vaccine costs (<or=$500), and S. aureus attack rates (>or=1%).

PMID:
20472028
PMCID:
PMC2896294
DOI:
10.1016/j.vaccine.2010.04.069
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center